Blood Neuropeptide Y Levels Did Not Predict PTSD Development in Two Large Military Cohorts | Research

The takeaway

Despite previous suggestions that neuropeptide Y (NPY) might be a resilience biomarker, two large prospective military cohort studies (N=892 and N=2,427) found that plasma NPY levels before and after deployment did not predict the development of PTSD symptoms.

N=3,319 across two cohorts — no PTSD prediction
Despite previous smaller studies suggesting NPY marks resilience, plasma NPY levels and trajectories did not predict PTSD symptoms over two years

What the researchers found

Across two large prospective cohorts (N=892 and N=2,427), three distinct plasma NPY (pNPY) trajectories were identified from measurements taken before and shortly after military deployment. However, in both cohorts:

- pNPY trajectories were not related to the level of PTSD symptoms over time

- Pre-deployment pNPY levels alone did not predict PTSD development

This challenges previous smaller studies that suggested high NPY levels might serve as a resilience biomarker. The current findings suggest limited usefulness of peripherally measured NPY (blood levels) for predicting PTSD risk, though central nervous system NPY levels might still be relevant.

Why it matters

The military desperately needs biomarkers that can identify soldiers at risk for PTSD before they deploy, enabling targeted prevention. NPY was a promising candidate based on smaller studies showing that Special Forces soldiers (known for resilience) had higher NPY levels. This large, well-designed study's null finding is important — it redirects the search for PTSD biomarkers away from peripheral NPY and suggests that the relationship between NPY and stress resilience may be more complex than previously thought, potentially involving brain-specific rather than blood-based measurements.

How the study worked

Two longitudinal prospective cohort studies of military personnel were analyzed. Data collection began before deployment, with follow-up assessments completed up to two years after deployment. Plasma NPY levels were measured before and shortly after deployment using standard assays. PTSD symptoms were assessed at multiple time points using validated instruments. Three distinct NPY trajectories were identified using latent trajectory modeling. The relationship between NPY trajectories and PTSD symptom development was examined in both cohorts.

What this study cannot tell us

Only peripheral (blood) NPY was measured, which may not reflect central nervous system NPY activity relevant to stress processing. The cohorts were predominantly male military personnel, limiting generalizability. PTSD symptoms were self-reported rather than clinician-diagnosed. The timing and frequency of NPY measurements may not capture dynamic stress-related NPY changes. Different assay methods between cohorts could introduce variability.

How to read the evidence

This is a high-quality study: two independent prospective cohort studies with large sample sizes (892 and 2,427), longitudinal design with pre-deployment baseline, and up to two years of follow-up. The null finding across two cohorts is robust and more reliable than the smaller positive studies it contradicts.

When this study was published

Published in 2018, this study remains an important reference in the NPY-PTSD literature. Its large sample size and prospective design make it one of the most definitive studies on this question to date.

The bigger picture

This study illustrates an important principle in biomarker research: findings from small, specialized studies don't always replicate in larger populations. The NPY-resilience hypothesis was built on studies of elite military populations, but in broader military cohorts, the relationship doesn't hold for peripheral measurements. This doesn't mean NPY is irrelevant to stress — it likely means that blood NPY levels are too far removed from brain NPY activity to serve as a useful biomarker. The search for PTSD biomarkers continues, with growing interest in neuroimaging and genetic approaches.

Questions still open

Would brain or cerebrospinal fluid NPY levels show a stronger relationship with PTSD development than blood levels?
Could genetic variants in the NPY gene system better predict PTSD vulnerability than circulating peptide levels?
Are there other neuropeptides or combinations of biomarkers that could predict PTSD risk more effectively?

Common questions

Why was neuropeptide Y thought to predict PTSD resilience?

Earlier smaller studies found that Special Forces soldiers and other resilient individuals had higher NPY levels under stress. NPY is known to counteract the stress hormone system (HPA axis) and reduce anxiety in animal studies. This led to the hypothesis that high NPY levels might protect against PTSD development. However, this larger study found the relationship doesn't hold when measured in blood in broader military populations.

Does this mean neuropeptide Y has no role in stress and PTSD?

Not necessarily. NPY in the brain almost certainly plays a role in stress responses — animal studies consistently show this. The problem may be that blood (peripheral) NPY doesn't accurately reflect what's happening with NPY in the brain. Blood NPY comes mainly from the sympathetic nervous system, while the stress-relevant NPY activity occurs in brain regions like the amygdala. Better measurement approaches, such as brain imaging or genetic studies, might still find a meaningful NPY-PTSD connection.

Read the original research

Biological profiling of plasma neuropeptide Y in relation to posttraumatic stress symptoms in two combat cohorts.

Biological psychology, 134, 72-79

View on PubMed ↗Publisher’s paper ↗

Citation

Reijnen, Alieke; Geuze, Elbert; Eekhout, Iris; Maihofer, Adam X; Nievergelt, Caroline M; Baker, Dewleen G; Vermetten, Eric. (2018). Biological profiling of plasma neuropeptide Y in relation to posttraumatic stress symptoms in two combat cohorts.. Biological psychology, 134, 72-79. https://doi.org/10.1016/j.biopsycho.2018.02.008